Sorry, you need to enable JavaScript to visit this website.
Skip to main content

Search

Astellas Pharma Inc. GLOBAL TOP

Astellas Innovation Management LLC

Main navigation

  • About AIM
  • Team
  • Our Strategy
  • Our Focus
  • Our Project
  • Contact Us

Common header menu

  • IMPORTANT NOTICE
  • WORLDWIDE
Important Notice

This website may contain information about medicines and their indications that are not approved in your country. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drugs including those under development.

Any information contained herein is not intended to provide medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider.

I Agree
logo
Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Cancel Click here to leave this site.

News

icon news
News / General News
Dec 03, 2019
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
Read More
icon news
News / General News
Dec 03, 2019
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
Read More
icon news
News / General News
Oct 31, 2019
PANDION AND ASTELLAS ANNOUNCE COLLABORATION TO DELIVER PANCREAS-TARGETED IMMUNOMODULATORS
Read More
icon news
News / General News
Oct 25, 2019
European Commission Approves Astellas’ XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Read More
icon news
News / General News
Oct 02, 2019
Astellas Commits Nearly $13 Million to Fund Boston-area Start-Up Innovation in Cell and Gene Therapy - Financial support for LabCentral Incubators builds on Astellas’ $1 Billion+ investment in Boston’s Life Science Community -
Read More
icon news
News / General News
Sep 30, 2019
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
Read More
View more >>

Bottom footer menu

  • SITE MAP
  • PRIVACY POLICY
  • TERMS OF USE
  • CONTACT US
Copyright © 2019 Astellas Innovation Management LLC. All Rights Reserved.